• Special Issue Topic
    Immunotherapy in Cancer Patients
    Submission Deadline: September 30, 2020

    Guest Editor

    Prof. Rossana Berardi E-Mail

    Professor in Medical Oncology and Director of the Postgraduate School of Medical Oncology at Università Politecnica Marche; Director of Department of Medical Oncology, Director of “Genetic Cancer” Center and Breast Unit Coordinator at Ospedali Riuniti of Ancona, Italy

    Research Keywords: thoracic cancer; breast cancer; neuroendocrine tumors; innovative therapies; COVID-19 and cancer


    About the Special Issue

    Immunotherapy in the last years improved outcome of cancer patients, inducing durable tumour responses, in particular in patients affected by NSCLC and melanoma. Immune checkpoint inhibitors regulate and stimulate the immune system to recognize and attack tumour cells. It is commonly better tolerated than chemotherapy and targeted therapy with a unique toxicity profile depending on their different of mechanism of activity.
    These toxicities, despite rare, can be sometimes disabling.
    However, some patients do not benefit from immunotherapy. Several original researches investigated the potential predictive role of clinical, pathological, laboratoristic factors to select responder patients.
    Notwithstanding, a validated predictive parameters do not detected.
    Immunotoxicity could involve all organs and systems requiring a specific management including steroids, immunomodulating therapy in multidisciplinary approach. Pathophysiology of immune-toxicity is still unclear. Parameters potentially associated with increased risk of immune-related adverse events are still under investigation.
    This special issue focus on predictive factors of response and toxicity in cancer patients treated with immunotherapy in order to improve the management of those subjects.

    logo.pngWomen for Oncology – Italy supports this special issue.

    Keywords: immunotherapy; immune-related toxicity; multidisciplinary approach

    Call for Papers

    Published Articles

    Open Access
    Review
    Gastrointestinal disorders as immune-related adverse events
    Immune checkpoint inhibitors, such as cytotoxic T-lymphocyte antigen 4 inhibitors, programmed cell death 1 inhibitors and programmed cell death-ligand 1 inhibitors, have recently emerged as novel drugs in the anti-cancer therapy. Their use in different types of advanced cancer has shown good results and an increase in survival rates. However, immune...
    Daniele Balducci ... Luca Maroni
    Online First: April 13, 2021 Explor Target Antitumor Ther. 2021;2:Online First
    DOI: https://doi.org/10.37349/etat.2021.00039
    View:77
    Download:1
    Times Cited: 0
    Open Access
    Review
    Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review
    Fungal compounds have long been used for centuries as food supplements. β-glucans have been identified as the most interesting molecules with beneficial effects in several chronic diseas...
    Valeria Cognigni ... Rossana Berardi
    Online First: March 08, 2021 Explor Target Antitumor Ther. 2021;2:Online First
    DOI: https://doi.org/10.37349/etat.2021.00036
    View:178
    Download:6
    Times Cited: 0
    Open Access
    Review
    Immunotherapy in gynecological cancers
    Immunotherapy has changed the natural history of several malignancies that, a decade ago, had a very poor prognosis, such as lung cancer and melanoma. Consequently, many attempts have been done to e...
    Domenica Lorusso ... Giovanni Scambia
    Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:48-64
    DOI: https://doi.org/10.37349/etat.2021.00033
    View:274
    Download:15
    Times Cited: 0
    Open Access
    Review
    Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC
    The introduction of immune checkpoint inhibitors (ICIs) in non-oncogene addicted non-small cell lung cancer (NSCLC) has revolutionized the treatment scenario and led to a meaningful improvement in p...
    Luca Cantini ... Rossana Berardi
    Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:1-25
    DOI: https://doi.org/10.37349/etat.2021.00030
    View:352
    Download:18
    Times Cited: 0
    Open Access
    Letter to the Editor
    Is hyperprogressive disease a specific phenomenom of immunotherapy?
    Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particula...
    Marta Brambilla ... Mario Occhipinti
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:427-433
    DOI: https://doi.org/10.37349/etat.2020.00027
    View:596
    Download:8
    Times Cited: 0
    Open Access
    Review
    An overview of immune checkpoint inhibitors in breast cancer
    Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-nega...
    Federica Miglietta ... Nicla La Verde
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:452-472
    DOI: https://doi.org/10.37349/etat.2020.00029
    View:717
    Download:28
    Times Cited: 0
    Open Access
    Case Report
    Pseudoprogression in lung cancer: a case report
    Immunotherapy dramatically changed the management of several malignancies including non-small cell lung cancer (NSCLC). Since immune checkpoint inhibitors have a different mechanism of action from c...
    Giulia Meoni ... Angela Stefania Ribecco
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:372-380
    DOI: https://doi.org/10.37349/etat.2020.00022
    View:485
    Download:11
    Times Cited: 0